Hyperpolarized $^{13}$C Metabolic MRI of the Human Heart
Initial Experience

Charles H. Cunningham, Justin Y.C. Lau, Albert P. Chen, Benjamin J. Geraghty, William J. Perks, Idan Roifman, Graham A. Wright, Kim A. Connelly

Rationale: Altered cardiac energetics is known to play an important role in the progression toward heart failure. A noninvasive method for imaging metabolic markers that could be used in longitudinal studies would be useful for understanding therapeutic approaches that target metabolism.

Objective: To demonstrate the first hyperpolarized $^{13}$C metabolic magnetic resonance imaging of the human heart.

Methods and Results: Four healthy subjects underwent conventional proton cardiac magnetic resonance imaging followed by $^{13}$C imaging and spectroscopic acquisition immediately after intravenous administration of a 0.1 mmol/kg dose of hyperpolarized [1-$^{13}$C]pyruvate. All subjects tolerated the procedure well with no adverse effects reported ≤1 month post procedure. The [1-$^{13}$C]pyruvate signal appeared within the chambers but not within the muscle. Imaging of the downstream metabolites showed $^{13}$C-bicarbonate signal mainly confined to the left ventricular myocardium, whereas the [1-$^{13}$C]lactate signal appeared both within the chambers and in the myocardium. The mean $^{13}$C image signal:noise ratio was 115 for [1-$^{13}$C]pyruvate, 56 for $^{13}$C-bicarbonate, and 53 for [1-$^{13}$C]lactate.

Conclusions: These results represent the first $^{13}$C images of the human heart. The appearance of $^{13}$C-bicarbonate signal after administration of hyperpolarized [1-$^{13}$C]pyruvate was readily detected in this healthy cohort (n=4). This shows that assessment of pyruvate metabolism in vivo in humans is feasible using current technology.

Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT02648009.

Key Words: heart failure ■ magnetic resonance imaging ■ metabolic imaging ■ metabolism ■ mitochondria

Understanding the role of altered intermediary metabolism in driving the transition from functional compensation to decompensated heart failure remains a promising avenue for the development of new therapies. The foundations of cardiac metabolism research are built on experiments in vitro and in the isolated perfused heart. However, to reproduce the effects of insulin and other hormones, plasma substrate levels, and workload/energy demand, in vivo assessment of cardiac metabolism is of paramount importance. This shows that assessment of pyruvate metabolism in vivo in humans is feasible using current technology.

Existing clinical imaging modalities for studying cardiac metabolism include positron emission tomography (PET) and magnetic resonance spectroscopy. Although providing unique insights into metabolism, both techniques suffer limitations. Magnetic resonance spectroscopy is only able to detect a limited range of biochemical reactions because of the inherent low sensitivity of this technique, and PET gives no information about the metabolic fate of the substrate beyond its cellular uptake. Furthermore, PET tracers deliver a dose of ionizing radiation, thus limiting repeated application. New methods for noninvasively probing the dynamics of cardiac metabolism in patients are still needed to augment the information currently available to the clinician.

Hyperpolarized carbon-13 ($^{13}$C) magnetic resonance imaging (MRI) is promising in this regard because it can give images showing the uptake of metabolic substrates and subsequent intracellular conversion into downstream products. The method relies on rapid dissolution dynamic nuclear polarization, which can provide a signal enhancement of >4 orders of magnitude. Measurements based on these images may give new information about the metabolic state of the heart in individual patients. In addition to its scientific value as a powerful tool for investigating normal cardiac metabolism, developments in preclinical models support the potential clinical value of $^{13}$C MRI in evaluating pathologies.
of the human heart, including myocardial viability after acute ischemia/reperfusion injury, early- and late-onset metabolic changes in the failing heart, and diabetic cardiomyopathy.

Using the substrate \([1-13C]\)pyruvate, which is an important intermediate of cellular metabolism, this study demonstrates the feasibility of observing, in a single examination, the following 4 different single-step enzyme-catalyzed reactions: pyruvate dehydrogenase complex (PDC), alanine aminotransferase, lactate dehydrogenase, and carbonic anhydrase. Of particular interest is the \(^{13}\)C bicarbonate signal that can be measured within the myocardium after an intravenous injection of \([1-13C]\)pyruvate, which is proportional to flux of pyruvate through PDC on the mitochondrial membrane. Because \(^{13}\)C MRI can be integrated into a conventional cardiovascular magnetic resonance (CMR) workup with only a small addition to the scan duration (eg, 10 minutes), the translation of this new form of MRI to patient studies is readily achievable, particularly where cardiac MRI is already used clinically. The first images of hyperpolarized \(^{13}\)C MRI in the human heart are presented in this pilot study in 4 healthy volunteers.

### Methods

Healthy subjects (n=4) were recruited and gave written informed consent under a protocol approved by the Sunnybrook Research Ethics Board and approved by Health Canada as a Clinical Trial Application. Subjects were instructed to eat as they normally would, and an oral carbohydrate load was administered 1 hour before the pyruvate injection as 35 g of Gatorade powder in water, containing 34 g of sucrose and dextrose, to be consistent with a protocol previously established for preclinical cardiac imaging. A 20-gauge intravenous catheter was placed in the left arm before each subject was positioned supine and feet first within a \(^{13}\)C volume transmit coil system (GE Healthcare, Cleveland, OH) installed on a GE MR750 3.0 T MRI scanner (GE Healthcare, Waukesha, WI). The \(^{13}\)C receiver coil system consisted of 2 separate paddles each containing 4 receiver elements (channels). One paddle was positioned on the anterior chest wall over the heart, and the other paddle under the upper left back. The left arm was fully extended, positioned directly by the side of the subject, and supported with the other paddle under the upper left back. The left arm was fully extended, positioned directly by the side of the subject, and supported with the other paddle under the upper left back.

For the 3 subsequent subjects, a 200-mL solution of \(^{13}\)C-urea, which was fixed on top of the anterior receiver coil housing. The dissolution of the polarized sample was initiated by the operator, and the quality control parameters were evaluated by the study pharmacist to ensure that the parameters were within specifications. On release, the dose syringe was rapidly loaded onto a Spectris Solaris power injector (Medrad, Indianola, PA), and the volume corresponding to a 0.1 mmol/kg dose was injected at 5 mL/s followed by a 25 mL saline flush at 5 mL/s.

The \(^{13}\)C imaging data acquisition was initiated at the end of the saline flush and was preceded by the same automated breath-hold instructions as used for the anatomic scanning. The data acquisition consisted of slice-selective spectral-spatial excitation of the \(^{13}\)C bicarbonate resonance in 6 slices of 1-cm thickness covering the LV. As a cardiac-gated sequence, the heart rate affects the scan time and sets an upper limit on the number of slices that can be acquired per heartbeat; the breath-hold duration sets the lower limit. To maintain a reasonable breath-hold duration, 3 slices were sequentially excited and imaged within each cardiac cycle (taking 2 cardiac cycles to complete all 6), with the cardiac trigger delay set such that the acquisition window was aligned with diastole. These 6 slices were then imaged at the \([1-13C]\)lactate and \([1-13C]\)pyruvate resonances, and the whole process was repeated 3×, taking 18 cardiac cycles to complete. The nominal spatial resolution was 8.8 × 8.8 mm in-plane with a 48-cm field-of-view.

Immediately after the \(^{13}\)C imaging, the residual hyperpolarized magnetization was used to acquire MR spectroscopic data from the whole heart. For the first subject, a slice-selective radiofrequency pulse was used (nominal flip angle=30°, 10-cm axial slab covering the heart), and the acquisition was not cardiac gated (repetition time=3 s). For the 3 subsequent subjects, a 200-ms nonselective radiofrequency pulse was used (nominal flip angle=18°), and the acquisition was cardiac gated, so the repetition times were ≈3 s (3–4 interbeat intervals, depending on heart rate). The shorter radiofrequency pulse was intended to excite the \(^{13}\)CO2 resonance, which was not observable in the data from the first subject. Whole-heart spectroscopy was used to provide adequate signal, given that much of the magnetization had likely been consumed by the preceding \(^{13}\)C imaging.

### Results

The 4 subjects recruited were male with no known cardiac history. Their mean age was 41 years (range 28–48). The mean LV ejection fraction was 61% (range 55%–66%). The LV end-diastolic and end-systolic volumes indexed to body surface area were 104 (range 82–115) and 41 (range 30–51) mL/m² respectively. The mean LV mass (indexed to body surface area) was 84 g/m² (range 62–93; Table).

Of the 4 doses injected, the mean polarization was 28% (range 17%–35%), pH was 7.35 (range 7.3–7.4), temperature was 36.4°C (range 36.0–37.0°C). The duration from dissolution to the start of imaging ranged from 66 to 71 s. Imaging scan duration ranged from 14 to 21 s. The injected volume of \([1-13C]\)pyruvate ranged from 29 to 37 mL to achieve 0.1 mmol/kg dose.

All subjects tolerated the procedure well. Two subjects noted a sweet taste after \([1-13C]\)pyruvate injection, which dissipated shortly afterward. No serious adverse effects were noted. During injection, there was no change in heart rate and no reported change in respiration. Noninvasive blood pressure measured before the CMR examination and...
post [1-13C]pyruvate injection did not vary significantly. No subject reported any adverse effects ≤1 month post [1-13C]pyruvate injection. For subject 04, the 13C imaging acquisition failed because of a scanner malfunction, but the subsequent 13C spectroscopy acquisition was successful.

Figure 1 shows time-integrated [1-13C]pyruvate, 13C-bicarbonate and [1-13C]lactate images from 2 of the 3 normal healthy volunteers with successful imaging acquisitions. These images were reconstructed from only the 4 channels on the anterior chest wall because the posterior channels gave insignificant signal. From the spatial distributions observed in the metabolite images, the 13C-bicarbonate signal appeared mainly confined to the LV myocardium, whereas the [1-13C]pyruvate appeared within the chambers (in the blood pool) but not within the muscle. In contrast, the [1-13C]lactate signal appeared both within the chambers and in the myocardium.

The maximum image signal:noise ratio (SNR) for each 13C-labeled metabolite across the subjects is plotted in Figure 2. This was calculated as the maximum pixel value for the corresponding metabolite image divided by the SD of the noise in the image background and serves as a benchmark for the image SNR that can be obtained in humans for this particular spatial resolution and at the polarization achievable currently. However, as the SNR in MRI varies linearly with the voxel volume (holding other parameters equal), this benchmark will be useful for the design of future experiments in patients. The modest spatial resolution used here (8.8×8.8 mm in-plane and 10 mm through plane) resulted in readily detectable metabolic conversion within the tissue and enabled observations about the spatial distribution

| Table. Subject Characteristics and Scan Details |
|-----------------------------------------------|
| Subject ID | 01 | 02 | 03 | 04 | Mean |
| Age, y      | 28 | 47 | 48 | 41 | 41   |
| Ejection fraction, % | 64 | 66 | 58 | 55 | 61   |
| Body surface area (BSA) | 1.79 | 1.95 | 2.12 | 1.95 | 1.95 |
| Left ventricular (LV) mass, g/m² | 62 | 93 | 89 | 92 | 84   |
| LV end-diastolic volume index, mL/m² | 82 | 107 | 110 | 115 | 104 |
| LV end-systolic volume index, mL/m² | 30 | 36 | 46 | 51 | 41   |
| LV stroke volume index, mL/m² | 52 | 70 | 64 | 64 | 63   |
| Heart rate, bpm | 69 | 57 | 55 | 47 | 57   |
| Dose given, mL | 29.3 | 33.0 | 37.0 | 33.0 | 33.1 |
| Start of injection from dissolution, s | 66 | 71 | 66 | 66 | 67   |
| Start of scan from dissolution, s | 77 | 84 | 95 | 82 | 85   |
| Duration of imaging scan, s | 14 | 17 | 19 | 21 | 18   |
| Start of spectroscopy from dissolution, s | 100 | 123 | 139 | 132 | 124 |

Figure 1. Representative 13C images displayed as color overlays on top of grayscale anatomic images in a midleft ventricle (LV) slice from subject 01 (A–C) and subject 03 (D–F). The [1-13C]pyruvate substrate was seen mainly in the blood pool within the cardiac chambers (A and D). Flux of pyruvate through the pyruvate dehydrogenase complex is reflected in the 13C-bicarbonate images (B and E), with signal predominantly in the wall of the LV. The [1-13C]lactate signal (C and F) appeared with a diffuse distribution covering the muscle and chambers.
of the substrate and products. The bicarbonate signal:noise in the right ventricular myocardium was insufficient for reliable assessment with the chosen spatial resolution and coil configuration.

Representative dynamic $^{13}$C spectra from one of the subjects are shown in Figure 3. Despite starting the spectroscopic acquisition after the completion of $^{13}$C imaging (and at least 90 s after dissolution), major metabolites from $[1-^{13}$C]pyruvate were all observed in the spectra (Figure 3A and 3B). The peaks observed correspond to $[1-^{13}$C]lactate (185 ppm), $[1-^{13}$C]alanine (179 ppm), $[1-^{13}$C]pyruvate (172 ppm), and $^{13}$C-bicarbonate (162 ppm). From one of the data sets using the nonselective radiofrequency pulse, $^{13}$CO$_2$ was also observed, and the pH calculated from the $^{13}$C-bicarbonate and $^{13}$CO$_2$ signals using the Henderson–Hasselbalch equation was 7.1. For 3 subjects with cardiac-gated spectroscopic acquisitions, the bicarbonate:pyruvate ratios remained relatively stable during the time points with sufficient SNR for quantification, ranging from 20 to 70 s. In contrast, the lactate:pyruvate ratio increased over a similar time frame for all subjects (Figure 3C and 3D).

Discussion

To the best of the authors’ knowledge, these results represent the first hyperpolarized $^{13}$C images of the human heart. $[1-^{13}$C]pyruvate metabolism in the LV myocardium, as indicated by the generation of the $^{13}$C-bicarbonate signal was readily detected in this healthy cohort. This suggests that this technology may one day allow a direct measure of flux through the PDC in the myocardium in vivo in humans. The opposing patterns observed in Figure 1 for the $[1-^{13}$C]pyruvate substrate and the $^{13}$C-bicarbonate product are consistent with rapid $[1-^{13}$C]pyruvate flux through the LV myocardial PDC (consuming the $[1-^{13}$C]pyruvate in the muscle). The diffuse appearance of the $[1-^{13}$C]lactate signal was consistent with previous data from a porcine model, where the $[1-^{13}$C]lactate signal seemed diffuse in both the blood and the tissue before ischemia. Understanding the more diffuse appearance of the $[1-^{13}$C]lactate signal would require further experiments, but it is clear that the largest component is in the blood pool (at the time points imaged here) and that any interpretation of whole-heart $^{13}$C spectra must take this into account.

Rationalization of the temporal evolution of the lactate:pyruvate and bicarbonate:pyruvate ratios observed in Figure 3C and 3D requires some degree of speculation. These data were acquired ≈1 minute after the initial bolus, so the spatial distribution of metabolites seen in Figure 1 had likely changed. A steady state was not observed for the lactate:pyruvate ratio, perhaps as a result of lactate dehydrogenase–mediated label exchange between the $[1-^{13}$C]pyruvate pool and the larger pre-existing lactate pool, resulting in the $[1-^{13}$C]lactate:$[1-^{13}$C]pyruvate ratio continuing to approach the endogenous lactate:pyruvate ratio. Unlike the reversible label exchange between pyruvate and lactate, the labeling of $^{13}$C-bicarbonate is the result of an irreversible forward flux, resulting in enrichment of $^{13}$CO$_2$ and $^{13}$C-bicarbonate. Through the normal physiology of aerobic respiration, intracellular $^{13}$CO$_2$ is continually exported and transported away via the blood, draining the $^{13}$C-bicarbonate pool. This negative feedback on the $^{13}$C-bicarbonate pool may account for the more stable trend in the $^{13}$C-bicarbonate:$[1-^{13}$C]pyruvate ratio over this time frame.

Importantly, no adverse events were recorded (except for the taste experienced by 2 subjects), and the injection and $^{13}$C
imaging were well tolerated. With this tool to assess in vivo
PDC flux in a rapid, safe and well-tolerated manner, longitudi-
dinal studies in humans incorporating this metabolic assess-
ment of the heart become feasible. The metabolic information
comes along with the detailed assessment of cardiac structure
and function from the conventional CMR assessment done
during the same scanning session. This augmented form of
CMR is anticipated to provide novel insights into how meta-
bolic changes relate to the process of functional decompensa-
tion leading to heart failure.

There are several limitations to the current technique
and to this study. To apply this method, specialized equip-
ment in the form of the SPINLab and 13C cardiac coils are
required, limiting the number of sites that are currently able
to do these studies. With the current polarization level and
imaging method, spatial resolution was limited because of a
trade-off with SNR (these will certainly improve in the future
as polarization levels increase and coils are improved). Thus,
imaging the ischemic heart to assess myocardial viability, or
other structures in the heart, such as the right ventricle, remain
technically challenging. Finally, this study only included nor-
mal volunteers, so the feasibility in a population with disease
remains to be shown.

The clinical potential for this technique remains consid-
erable. As demonstrated by our previous work in porcine models
of heart failure,12 as well as work by other groups,19 the ability
to perform repeated assessments of PDC flux will provide im-
portant insights into disease pathogenesis that can potentially
facilitate treatment strategies in the form of PDC modula-
tors. A significant body of work implicates PDC activity as
an important determinant of cardiac function, particularly in
states where insulin resistance occurs.20 For instance, in in-
sulin-resistant ob/ob mice, enhanced fatty acid metabolism at
the expense of glucose oxidation is associated with impaired
contractile function.21 Indeed, there is a growing body of evi-
dence to suggest that improving contractile function may be
associated with the normalization of PDC flux. Changes in
PDC activity may not only be a marker for abnormal cellular
metabolism and increased oxidative stress it may also serve as
a therapeutic target to prevent the development of heart failure
in states where PDC activity is impaired.22 However, as the
relative utilization of fatty acids and carbohydrates shifts de-
pending on the pathogenesis and stage of disease,3 the appro-
priate therapy will require individualization for the particular
patient, and this is where CMR plus 13C MRI may be clinically
valuable.

Conclusions
These results represent the first 13C images of the human
heart. The appearance of hyperpolarized signals of both
13CO2 and 13C-bicarbonate from [1-13C]pyruvate suggests that
this technology may one day allow a direct measure of flux through the PDC in the myocardium in vivo in humans.

Acknowledgments
We thank Tracey Rideout, Sergio DeFigueiredo, and Stephanie Vidotto for pharmacy technician support for this study, Julie Green for coordinating the study, and Ruby Endre and Garry Detzler for MR technician support.

Sources of Funding
This study was supported by the Heart and Stroke Foundation of Canada and Canadian Institutes of Health Research MOP133-504. K.A. Connelly is supported by a CIHR New Investigator award.

Disclosures
A.P. Chen is an employee of GE Healthcare. The other authors report no conflicts.

References
1. Stanley WC, Chandler MP. Energy metabolism in the normal and failing heart: potential for therapeutic interventions. *Heart Fail Rev.* 2002;7:115–130.
2. Ashrafian H, Fremeaux MP, Opie LH. Metabolic mechanisms in heart failure. *Circulation.* 2007;116:434–448. doi: 10.1161/CIRCULATIONAHA.107.070279.
3. Ardehali H, Sabbah HN, Burke MA, Sarma S, Liu JP, Cleland JG, Maggioni A, Fonarow GC, Abel ED, Campia U, Gheorghiade M. Targeting myocardial substrate metabolism in heart failure: potential for new therapies. *Eur J Heart Fail.* 2012;14:120–129. doi: 10.1093/euheartj/hft173.
4. Doenst T, Nguyen TD, Abel ED. Cardiac metabolism in heart failure: implications beyond ATP production. *Circ Res.* 2013;113:709–724. doi: 10.1161/CIRCRESAHA.113.300376.
5. Garlick PB, Radda GK, Seeley PJ. Phosphorus NMR studies on perfused heart. *Biochem Biophys Res Commun.* 1977;104:1256–1262.
6. Bailey IA, Gadian DG, Matthews PM, Radda GK, Seeley PJ. Studies of metabolism in the isolated, perfused rat heart using 13C NMR. *FEBS Lett.* 1981;123:315–318.
7. Ardenkjaer-Larsen JH, Fridlund B, Gram A, Hansson G, Hansson L, Lerche MH, Servin R, Thanning M, Golman K. Increase in signal-to-noise ratio of >10000 times in liquid-state NMR. *Proc Natl Acad Sci U S A.* 2003;100:10158–10163. doi: 10.1073/pnas.1733835100.
8. Merritt ME, Harrison C, Storey C, Jeffrey FM, Sherry AD, Malley CR. Hyperpolarized 13C allows a direct measure of flux through a single enzyme-catalyzed step by NMR. *Proc Natl Acad Sci U S A.* 2007;104:19773–19777. doi: 10.1073/pnas.0706235104.
9. Golman K, Petersson JS, Magnusson P, Johansson E, Akeson P, Chai CM, Hansson G, Månsson S. Cardiac metabolism measured noninvasively by hyperpolarized 13C MRI. *Magn Reson Med.* 2008;59:1005–1013. doi: 10.1002/mrm.21460.
10. Schroeder MA, Cochlin LE, Heather LC, Clarke K, Radda GK, Tyler DJ. In vivo assessment of pyruvate dehydrogenase flux in the heart using hyperpolarized carbon-13 magnetic resonance. *Proc Natl Acad Sci U S A.* 2008;105:12051–12056. doi: 10.1073/pnas.0808593105.
11. Schroeder MA, Clarke K, Neubauer S, Tyler DJ. Hyperpolarized magnetic resonance: a novel technique for the in vivo assessment of cardiovascular disease. *Circulation.* 2011;124:1580–1594. doi: 10.1161/CIRCULATIONAHA.111.024919.
12. Lau AZ, Chen AP, Barry J, Graham JJ, Dominguez-Viqueira W, Ghugre NR, Wright GA, Cunningham CH. Reproducibility study for free-breathing measurements of pyruvate metabolism using hyperpolarized (13)C in the heart. *Magn Reson Med.* 2013;69:1063–1071. doi: 10.1002/mrm.23642.
13. Schroeder MA, Lau AZ, Chen AP, Gu Y, Nagendran J, Barry J, Hu X, Dyck JR, Tyler DJ, Clarke K, Connelly KA, Wright GA, Cunningham CH. Hyperpolarized (13)C magnetic resonance reveals early- and late-onset changes to in vivo pyruvate metabolism in the failing heart. *Eur J Heart Fail.* 2013;15:130–140. doi: 10.1093/euheartj/hfs192.
14. Le Page LM, Rider OJ, Lewis AJ, Ball V, Clarke K, Johansson E, Carr CA, Heather LC, Tyler DJ. Increasing pyruvate dehydrogenase flux as a treatment for diabetic cardiomyopathy: A Combined 13C Hyperpolarized Magnetic Resonance and Echocardiography Study. *Diabetes.* 2015;64:2735–2743. doi: 10.2337/db14-1560.
15. Lau AZ, Chen AP, Ghugre NR, Ramanan V, Lam WW, Connelly KA, Wright GA, Cunningham CH. Rapid multislice imaging of hyperpolarized 13C pyruvate and bicarbonate in the heart. *Magn Reson Med.* 2010;64:1323–1331. doi: 10.1002/mrm.22525.
16. Tropp J, Calderon P, Carvajal L, Robb F, Larson PEZ, Shia P, Vigneron DB, Nelson SJ. A carbon receive array of 8 elements, interoperable with proton scanning, for human temporal lobe. *Proceedings of the 20th Annual Meeting of ISMRM*; Melbourne, Australia. 2012. Abstract 2658.
17. Ardenkjaer-Larsen JH, Leach AM, Clarke N, Urbahn J, Anderson D, Skloss TW. Dynamic nuclear polarization polarizer for sterile use intent. *NMR Biomed.* 2011;24:927–932.
18. Witney TH, Kettunen MI, Brindle KM. Kinetic modeling of hyperpolarized 13C label exchange between pyruvate and lactate in tumor cells. *J Biol Chem.* 2011;286:24572–24580. doi: 10.1074/jbc.M111.237727.
19. Rider OJ, Tyler DJ. Clinical implications of cardiac hyperpolarized magnetic resonance imaging. *J Cardiovasc Magn Reson.* 2013;15:93. doi: 10.1186/1532-429X-15-93.
20. Taegtmeyer H, McNulty P, Young ME. Adaptation and maladaptation of the heart in diabetes: Part I: general concepts. *Circulation.* 2002;105:1727–1733.
21. Mazumder PK, O’Neill BT, Roberts MW, Buchanan J, Yun UJ, Cookey RC, Boudina S, Abel ED. Impaired cardiac efficiency and increased fatty acid oxidation in insulin-resistant ob/ob mouse hearts. *Diabetes.* 2004;53:2366–2374.
22. Lewis AJ, Neubauer S, Tyler DJ, Rider OJ. Pyruvate dehydrogenase as a therapeutic target for obesity cardiomyopathy. *Expert Opin Ther Targets.* 2016;20:755–766. doi: 10.1517/14728222.2016.1126248.
Hyperpolarized $^{13}$C Metabolic MRI of the Human Heart: Initial Experience
Charles H. Cunningham, Justin Y.C. Lau, Albert P. Chen, Benjamin J. Geraghty, William J. Perks, Idan Roifman, Graham A. Wright and Kim A. Connelly

*Circ Res.* 2016;119:1177-1182; originally published online September 15, 2016; doi: 10.1161/CIRCRESAHA.116.309769

*Circulation Research* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2016 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circres.ahajournals.org/content/119/11/1177
Free via Open Access

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Circulation Research* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to *Circulation Research* is online at:
http://circres.ahajournals.org//subscriptions/